Previous 10 | Next 10 |
ALPHARETTA, Ga., July 11, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that George Lasezkay, Pharm.D., J.D.,...
- XIPERE ® is referred to as Arcatus (ARVN001) by Arctic Vision – ALPHARETTA, Ga., July 10, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye thr...
2023-07-03 07:40:18 ET Summary Cornerstone Strategic Value Fund is a highly controversial fund with its ever-declining share price and 4-star Morningstar rating. The fund's performance relies on it trading at a premium to its NAV, a situation that may or may not continue indefinit...
2023-06-26 10:50:35 ET Summary The Gabelli Multimedia fund (GGT) is, right now, the most over-priced technology and multimedia focused CEF in history. The fund has actually lost NAV during one of the great bull markets in technology this year. GGT's NAV started the year at $3.89 a...
2023-06-04 07:42:44 ET Summary Change is inevitable and this article discusses how my investing strategy, goals, and risk tolerance have changed to adapt over time. My investment strategy shifted from capital appreciation to generating passive income for retirement, focusing on hi...
- U.S. Clinical Sites Screening Treatment-Experienced Participants with Wet AMD - - ODYSSEY Topline Results Expected in Q3 2024 - ALPHARETTA, Ga., June 01, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery o...
2023-05-27 08:55:54 ET Summary We share updated data on more than 10 of the biggest and most-popular big-yield CEFs. We have a special focus on Cohen & Steers Infrastructure Fund (UTF), currently yielding over 8%, and trading at a significant discount to its net asset value. ...
- Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected to Open Enrollment in Q2 2023 - - Positive Safety Data, Duration and Biologic Effect of CLS-AX Over 6 Months in OASIS Phase 1/2a Extension Study Highlighted in Presentations at Recent Medical Meetings - - Man...
ALPHARETTA, Ga., May 09, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that George Lasezkay, Pharm.D., J.D., ...
2023-05-04 11:18:55 ET Summary Icahn Enterprises crashed as the short seller report surfaced. The yield has gone to an incredible 25%. Can the legend Carl Icahn maintain this and take on Hindenburg? Let's find out. The market has a way of turning tables on the best o...
News, Short Squeeze, Breakout and More Instantly...
Cornerstone Strategic Value Fund Inc. Company Name:
CLM Stock Symbol:
NYSE Market:
ALPHARETTA, Ga., July 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), has opened registration for its virtual key opinion l...
ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today the appointment of Glenn C. Yiu, M.D....
- Webinar to be held on Wednesday, July 24, 2024 at 8:00 am ET - - Retina Specialists to Provide Insights and Real-World Experience with Suprachoroidal Drug Delivery - - Target Profile for CLS-AX in Wet AMD Landscape and Potential Opportunities for Clearside Pipeline Expansion - ...